BioSpace News Archive

Scientists Develop Proprietary Technology, Addressing Issues on the Rise with Unregulated CBD and Delta-8-THC based Products

Products containing cannabidiol (CBD) and other legal hemp-derived THC alternatives have become increasingly popular and are appearing in stores and online throughout the United States.

April 23, 2024
·
3 min read
Pharm Country

Curio Digital Therapeutics Inc. Announces the U.S. Food and Drug Administration (FDA) Clearance of MamaLift Plus™, the First Prescription Digital Therapeutic Authorized for the Treatment of Postpartum Depression (PPD)

Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM.

April 23, 2024
·
7 min read
Biotech Bay

Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development

Xaira Therapeutics launched on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies.

April 23, 2024
·
7 min read
Astellas’ XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the European Commission (EC) has approved a label extension for XTANDI™ (enzalutamide) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage-radiotherapy.

April 23, 2024
·
11 min read
Business

Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)

Hanmi Pharmaceutical announces Clinical Trial Collaboration with MSD to evaluate ‘BH3120' in combination with KEYTRUDA in phase 1 clinical trial in patients with progressive or metastatic solid tumors

April 23, 2024
·
4 min read
Genetown

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

Centessa Pharmaceuticals plc announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares, each representing one ordinary share, at a price to the public of $9.25 per ADS.

April 23, 2024
·
4 min read
Job Trends

GenScript Singapore’s Open Day Reveals Pioneering AI Capabilities in Recombinant Protein Production and Drug Discovery

GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from Singapore.

April 23, 2024
·
3 min read